{"transactions":[{"id":2761365,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Stock Option (right to buy)","published_at":"2021-04-02T20:42:02.000Z","date":"2021-04-01","kind":"exercise","acquired":false,"shares":33001,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F25","text":"The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 175,117 shares as of April 1, 2021."}],"balance_after":6116,"derivative":{"exercise_price":6.83,"expiration_date":"2026-02-02","underlying":"Common Stock","underlying_shares":33001},"source":{"system":"sec-edgar","filing":"0001209191-21-024888","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":30,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919121024888/doc4.xml","form_type":"4"}},{"id":2761364,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Stock Option (right to buy)","published_at":"2021-04-02T20:42:02.000Z","date":"2021-04-01","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F24","text":"The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 39,937 shares as of April 1, 2021."}],"balance_after":51000,"derivative":{"exercise_price":14.58,"expiration_date":"2028-12-17","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-21-024888","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":29,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919121024888/doc4.xml","form_type":"4"}},{"id":2761363,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Stock Option (right to buy)","published_at":"2021-04-02T20:42:02.000Z","date":"2021-04-01","kind":"exercise","acquired":false,"shares":21000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F23","text":"The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 58,906 shares as of April 1, 2021."}],"balance_after":29090,"derivative":{"exercise_price":18.3,"expiration_date":"2027-12-11","underlying":"Common Stock","underlying_shares":21000},"source":{"system":"sec-edgar","filing":"0001209191-21-024888","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":28,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919121024888/doc4.xml","form_type":"4"}},{"id":2761362,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Stock Option (right to buy)","published_at":"2021-04-02T20:42:02.000Z","date":"2021-04-01","kind":"exercise","acquired":false,"shares":33000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F22","text":"The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 115,000 shares as of April 1, 2021."}],"balance_after":39000,"derivative":{"exercise_price":13.88,"expiration_date":"2027-01-05","underlying":"Common Stock","underlying_shares":33000},"source":{"system":"sec-edgar","filing":"0001209191-21-024888","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":27,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919121024888/doc4.xml","form_type":"4"}},{"id":2761361,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2021-04-02T20:42:02.000Z","date":"2021-04-01","kind":"sale","acquired":false,"shares":124,"price":85.76,"value":10634.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":162388,"source":{"system":"sec-edgar","filing":"0001209191-21-024888","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919121024888/doc4.xml","form_type":"4"}},{"id":2761360,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2021-04-02T20:42:02.000Z","date":"2021-04-01","kind":"sale","acquired":false,"shares":1213,"price":84.73,"value":102777.49,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F20","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.55 to $85.29, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price."}],"balance_after":162512,"source":{"system":"sec-edgar","filing":"0001209191-21-024888","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919121024888/doc4.xml","form_type":"4"}},{"id":2761359,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2021-04-02T20:42:02.000Z","date":"2021-04-01","kind":"sale","acquired":false,"shares":2258,"price":83.85,"value":189333.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F19","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.52 to $84.50, inclusive.  Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price."}],"balance_after":163725,"source":{"system":"sec-edgar","filing":"0001209191-21-024888","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919121024888/doc4.xml","form_type":"4"}},{"id":2761358,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2021-04-02T20:42:02.000Z","date":"2021-04-01","kind":"sale","acquired":false,"shares":3361,"price":82.77,"value":278189.97,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F18","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.415 to $83.37, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price."}],"balance_after":165983,"source":{"system":"sec-edgar","filing":"0001209191-21-024888","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919121024888/doc4.xml","form_type":"4"}},{"id":2761357,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2021-04-02T20:42:02.000Z","date":"2021-04-01","kind":"sale","acquired":false,"shares":6768,"price":81.87,"value":554096.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F17","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.4025 to $82.385, inclusive.  Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price."}],"balance_after":169344,"source":{"system":"sec-edgar","filing":"0001209191-21-024888","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919121024888/doc4.xml","form_type":"4"}},{"id":2761356,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2021-04-02T20:42:02.000Z","date":"2021-04-01","kind":"sale","acquired":false,"shares":1965,"price":80.85,"value":158870.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F16","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.3925 to $81.30, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price."}],"balance_after":176112,"source":{"system":"sec-edgar","filing":"0001209191-21-024888","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919121024888/doc4.xml","form_type":"4"}},{"id":2761355,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2021-04-02T20:42:02.000Z","date":"2021-04-01","kind":"exercise","acquired":true,"shares":33001,"price":6.83,"value":225396.83,"ownership":{"direct":true},"balance_after":178077,"source":{"system":"sec-edgar","filing":"0001209191-21-024888","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919121024888/doc4.xml","form_type":"4"}},{"id":2761354,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2021-04-02T20:42:02.000Z","date":"2021-04-01","kind":"sale","acquired":false,"shares":123,"price":85.14,"value":10472.22,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":145076,"source":{"system":"sec-edgar","filing":"0001209191-21-024888","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919121024888/doc4.xml","form_type":"4"}},{"id":2761353,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2021-04-02T20:42:02.000Z","date":"2021-04-01","kind":"sale","acquired":false,"shares":1049,"price":83.98,"value":88095.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F15","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.69 to $84.57, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price."}],"balance_after":145199,"source":{"system":"sec-edgar","filing":"0001209191-21-024888","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919121024888/doc4.xml","form_type":"4"}},{"id":2761352,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2021-04-02T20:42:02.000Z","date":"2021-04-01","kind":"sale","acquired":false,"shares":951,"price":82.87,"value":78809.37,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F14","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.605 to $83.37, inclusive.  Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price."}],"balance_after":146248,"source":{"system":"sec-edgar","filing":"0001209191-21-024888","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919121024888/doc4.xml","form_type":"4"}},{"id":2761351,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2021-04-02T20:42:02.000Z","date":"2021-04-01","kind":"sale","acquired":false,"shares":2644,"price":81.95,"value":216675.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.52 to $82.46, inclusive.  Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price."}],"balance_after":147199,"source":{"system":"sec-edgar","filing":"0001209191-21-024888","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919121024888/doc4.xml","form_type":"4"}},{"id":2761350,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2021-04-02T20:42:02.000Z","date":"2021-04-01","kind":"sale","acquired":false,"shares":700,"price":80.73,"value":56511.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.44 to $81.415, inclusive.  Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price."}],"balance_after":149843,"source":{"system":"sec-edgar","filing":"0001209191-21-024888","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919121024888/doc4.xml","form_type":"4"}},{"id":2761349,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2021-04-02T20:42:02.000Z","date":"2021-04-01","kind":"exercise","acquired":true,"shares":10000,"price":14.58,"value":145800.0,"ownership":{"direct":true},"balance_after":150543,"source":{"system":"sec-edgar","filing":"0001209191-21-024888","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919121024888/doc4.xml","form_type":"4"}},{"id":2761348,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2021-04-02T20:42:02.000Z","date":"2021-04-01","kind":"sale","acquired":false,"shares":963,"price":84.87,"value":81729.81,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.55 to $85.43, inclusive.  Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price."}],"balance_after":140543,"source":{"system":"sec-edgar","filing":"0001209191-21-024888","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919121024888/doc4.xml","form_type":"4"}},{"id":2761347,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2021-04-02T20:42:02.000Z","date":"2021-04-01","kind":"sale","acquired":false,"shares":1724,"price":83.72,"value":144333.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.37 to $84.17, inclusive.  Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price."}],"balance_after":141506,"source":{"system":"sec-edgar","filing":"0001209191-21-024888","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919121024888/doc4.xml","form_type":"4"}},{"id":2761346,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2021-04-02T20:42:02.000Z","date":"2021-04-01","kind":"sale","acquired":false,"shares":2728,"price":82.63,"value":225414.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.3175 to $82.92, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price."}],"balance_after":143230,"source":{"system":"sec-edgar","filing":"0001209191-21-024888","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919121024888/doc4.xml","form_type":"4"}},{"id":2761345,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2021-04-02T20:42:02.000Z","date":"2021-04-01","kind":"sale","acquired":false,"shares":4818,"price":81.83,"value":394256.94,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.31 to $82.30, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price."}],"balance_after":145958,"source":{"system":"sec-edgar","filing":"0001209191-21-024888","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919121024888/doc4.xml","form_type":"4"}},{"id":2761344,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2021-04-02T20:42:02.000Z","date":"2021-04-01","kind":"sale","acquired":false,"shares":1256,"price":80.82,"value":101509.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.305 to $81.16, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price."}],"balance_after":150776,"source":{"system":"sec-edgar","filing":"0001209191-21-024888","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919121024888/doc4.xml","form_type":"4"}},{"id":2761343,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2021-04-02T20:42:02.000Z","date":"2021-04-01","kind":"exercise","acquired":true,"shares":21000,"price":18.3,"value":384300.0,"ownership":{"direct":true},"balance_after":152032,"source":{"system":"sec-edgar","filing":"0001209191-21-024888","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919121024888/doc4.xml","form_type":"4"}},{"id":2761342,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2021-04-02T20:42:02.000Z","date":"2021-04-01","kind":"sale","acquired":false,"shares":1067,"price":84.94,"value":90630.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.535 to $85.38, inclusive.  Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price."}],"balance_after":131032,"source":{"system":"sec-edgar","filing":"0001209191-21-024888","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919121024888/doc4.xml","form_type":"4"}},{"id":2761341,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2021-04-02T20:42:02.000Z","date":"2021-04-01","kind":"sale","acquired":false,"shares":3234,"price":83.91,"value":271364.94,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.455 to $84.45, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price."}],"balance_after":132099,"source":{"system":"sec-edgar","filing":"0001209191-21-024888","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919121024888/doc4.xml","form_type":"4"}},{"id":2761340,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2021-04-02T20:42:02.000Z","date":"2021-04-01","kind":"sale","acquired":false,"shares":3233,"price":82.76,"value":267563.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.3975 to $83.28, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price."}],"balance_after":135333,"source":{"system":"sec-edgar","filing":"0001209191-21-024888","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919121024888/doc4.xml","form_type":"4"}},{"id":2761339,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2021-04-02T20:42:02.000Z","date":"2021-04-01","kind":"sale","acquired":false,"shares":8266,"price":81.89,"value":676902.74,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.39 to $82.375, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price."}],"balance_after":138566,"source":{"system":"sec-edgar","filing":"0001209191-21-024888","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919121024888/doc4.xml","form_type":"4"}},{"id":2761338,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2021-04-02T20:42:02.000Z","date":"2021-04-01","kind":"sale","acquired":false,"shares":2010,"price":80.79,"value":162387.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.35 to $81.30, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price."}],"balance_after":146832,"source":{"system":"sec-edgar","filing":"0001209191-21-024888","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919121024888/doc4.xml","form_type":"4"}},{"id":2761337,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2021-04-02T20:42:02.000Z","date":"2021-04-01","kind":"exercise","acquired":true,"shares":33000,"price":13.88,"value":458040.0,"ownership":{"direct":true},"balance_after":148842,"source":{"system":"sec-edgar","filing":"0001209191-21-024888","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919121024888/doc4.xml","form_type":"4"}},{"id":2806310,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Restricted Stock Unit","published_at":"2021-03-05T17:52:06.000Z","date":"2021-03-03","kind":"grant","acquired":true,"shares":12250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On March 3, 2021, the reporting person was granted 12,250 Restricted Stock Units (\"RSUs\") pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments."},{"field":"date","element":"transactionDate","label":"F2","text":"On March 3, 2021, the reporting person was granted 12,250 Restricted Stock Units (\"RSUs\") pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 3, 2021, the reporting person was granted 12,250 Restricted Stock Units (\"RSUs\") pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On March 3, 2021, the reporting person was granted 12,250 Restricted Stock Units (\"RSUs\") pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments."}],"balance_after":12250,"derivative":{"underlying":"Common Stock","underlying_shares":12250},"source":{"system":"sec-edgar","filing":"0001209191-21-018324","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919121018324/doc4.xml","form_type":"4"}},{"id":2806309,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Stock Option (right to buy)","published_at":"2021-03-05T17:52:06.000Z","date":"2021-03-03","kind":"grant","acquired":true,"shares":73500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on March 3, 2021 with respect to 73,500 shares of Common Stock, with 25% vesting on January 1, 2022 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter."}],"balance_after":73500,"derivative":{"exercise_price":57.71,"expiration_date":"2031-03-02","underlying":"Common Stock","underlying_shares":73500},"source":{"system":"sec-edgar","filing":"0001209191-21-018324","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919121018324/doc4.xml","form_type":"4"}},{"id":2871933,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Stock Option (right to buy)","published_at":"2021-02-09T20:38:24.000Z","date":"2021-02-09","kind":"exercise","acquired":false,"shares":21000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 54,475 shares as of February 9, 2021."}],"balance_after":50090,"derivative":{"exercise_price":18.295,"expiration_date":"2027-12-11","underlying":"Common Stock","underlying_shares":21000},"source":{"system":"sec-edgar","filing":"0001209191-21-009085","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919121009085/doc4.xml","form_type":"4"}},{"id":2871932,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2021-02-09T20:38:24.000Z","date":"2021-02-09","kind":"sale","acquired":false,"shares":11489,"price":75,"value":861675.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":117920,"source":{"system":"sec-edgar","filing":"0001209191-21-009085","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919121009085/doc4.xml","form_type":"4"}},{"id":2871931,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2021-02-09T20:38:24.000Z","date":"2021-02-09","kind":"exercise","acquired":true,"shares":21000,"price":18.295,"value":384195.0,"ownership":{"direct":true},"balance_after":129409,"source":{"system":"sec-edgar","filing":"0001209191-21-009085","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919121009085/doc4.xml","form_type":"4"}},{"id":2881942,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Stock Option (right to buy)","published_at":"2021-02-03T21:38:12.000Z","date":"2021-02-01","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F14","text":"The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 36,979 shares as of February 1, 2021."}],"balance_after":61000,"derivative":{"exercise_price":14.58,"expiration_date":"2028-12-17","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-21-007637","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919121007637/doc4.xml","form_type":"4"}},{"id":2881941,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Stock Option (right to buy)","published_at":"2021-02-03T21:38:12.000Z","date":"2021-02-01","kind":"exercise","acquired":false,"shares":33000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and vested in full on January 6, 2021."}],"balance_after":72000,"derivative":{"exercise_price":13.88,"expiration_date":"2027-01-05","underlying":"Common Stock","underlying_shares":33000},"source":{"system":"sec-edgar","filing":"0001209191-21-007637","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919121007637/doc4.xml","form_type":"4"}},{"id":2881940,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Stock Option (right to buy)","published_at":"2021-02-03T21:38:12.000Z","date":"2021-02-01","kind":"exercise","acquired":false,"shares":66000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and vested in full on February 3, 2020."}],"balance_after":39117,"derivative":{"exercise_price":6.83,"expiration_date":"2026-02-02","underlying":"Common Stock","underlying_shares":66000},"source":{"system":"sec-edgar","filing":"0001209191-21-007637","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919121007637/doc4.xml","form_type":"4"}},{"id":2881939,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2021-02-03T21:38:12.000Z","date":"2021-02-01","kind":"sale","acquired":false,"shares":755,"price":65.07,"value":49127.85,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.94 to $65.34, inclusive.  Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2021 at each separate price."}],"balance_after":108409,"source":{"system":"sec-edgar","filing":"0001209191-21-007637","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919121007637/doc4.xml","form_type":"4"}},{"id":2881938,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2021-02-03T21:38:12.000Z","date":"2021-02-01","kind":"sale","acquired":false,"shares":2386,"price":64.18,"value":153133.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.83 to $64.795, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2021 at each separate price."}],"balance_after":109164,"source":{"system":"sec-edgar","filing":"0001209191-21-007637","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919121007637/doc4.xml","form_type":"4"}},{"id":2881937,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2021-02-03T21:38:12.000Z","date":"2021-02-01","kind":"sale","acquired":false,"shares":2326,"price":63.44,"value":147561.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.81 to $63.71, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2021 at each separate price."}],"balance_after":111550,"source":{"system":"sec-edgar","filing":"0001209191-21-007637","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919121007637/doc4.xml","form_type":"4"}},{"id":2881936,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2021-02-03T21:38:12.000Z","date":"2021-02-01","kind":"exercise","acquired":true,"shares":10000,"price":14.58,"value":145800.0,"ownership":{"direct":true},"balance_after":113876,"source":{"system":"sec-edgar","filing":"0001209191-21-007637","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919121007637/doc4.xml","form_type":"4"}},{"id":2881935,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2021-02-03T21:38:12.000Z","date":"2021-02-01","kind":"sale","acquired":false,"shares":2827,"price":65.05,"value":183896.35,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.76 to $65.56, inclusive.  Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2021 at each separate price."}],"balance_after":103876,"source":{"system":"sec-edgar","filing":"0001209191-21-007637","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919121007637/doc4.xml","form_type":"4"}},{"id":2881934,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2021-02-03T21:38:12.000Z","date":"2021-02-01","kind":"sale","acquired":false,"shares":8366,"price":64.16,"value":536762.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.75 to $64.72, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2021 at each separate price."}],"balance_after":106703,"source":{"system":"sec-edgar","filing":"0001209191-21-007637","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919121007637/doc4.xml","form_type":"4"}},{"id":2881933,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2021-02-03T21:38:12.000Z","date":"2021-02-01","kind":"sale","acquired":false,"shares":6617,"price":63.34,"value":419120.78,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.74 to $63.71, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2021 at each separate price."}],"balance_after":115069,"source":{"system":"sec-edgar","filing":"0001209191-21-007637","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919121007637/doc4.xml","form_type":"4"}},{"id":2881932,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2021-02-03T21:38:12.000Z","date":"2021-02-01","kind":"exercise","acquired":true,"shares":33000,"price":13.88,"value":458040.0,"ownership":{"direct":true},"balance_after":121686,"source":{"system":"sec-edgar","filing":"0001209191-21-007637","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919121007637/doc4.xml","form_type":"4"}},{"id":2881931,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2021-02-03T21:38:12.000Z","date":"2021-02-01","kind":"sale","acquired":false,"shares":5312,"price":65.01,"value":345333.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.72 to $65.40, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2021 at each separate price."}],"balance_after":88686,"source":{"system":"sec-edgar","filing":"0001209191-21-007637","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919121007637/doc4.xml","form_type":"4"}},{"id":2881930,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2021-02-03T21:38:12.000Z","date":"2021-02-01","kind":"sale","acquired":false,"shares":15594,"price":64.11,"value":999731.34,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.69 to $64.65, inclusive.  Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2021 at each separate price."}],"balance_after":93998,"source":{"system":"sec-edgar","filing":"0001209191-21-007637","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919121007637/doc4.xml","form_type":"4"}},{"id":2881929,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2021-02-03T21:38:12.000Z","date":"2021-02-01","kind":"sale","acquired":false,"shares":10476,"price":63.31,"value":663235.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.69 to $63.685, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2021 at each separate price."}],"balance_after":109592,"source":{"system":"sec-edgar","filing":"0001209191-21-007637","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919121007637/doc4.xml","form_type":"4"}},{"id":2881928,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2021-02-03T21:38:12.000Z","date":"2021-02-01","kind":"exercise","acquired":true,"shares":66000,"price":6.83,"value":450780.0,"ownership":{"direct":true},"balance_after":120068,"source":{"system":"sec-edgar","filing":"0001209191-21-007637","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919121007637/doc4.xml","form_type":"4"}},{"id":2920660,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Restricted Stock Unit (performance-based)","published_at":"2021-01-05T20:55:19.000Z","date":"2020-12-31","kind":"exercise","acquired":false,"shares":4792,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"On March 21, 2018, the reporting person was granted 14,375 PRSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each PRSU represents a contingent right to receive one share of the Company's common stock upon vesting, with one-third of the PRSUs vesting upon each achievement of the Performance Milestones through the calendar year 2020. On December 31, 2020, one of the Performance Milestones was achieved, resulting in the vesting of 4,792 PRSUs."},{"field":"date","element":"transactionDate","label":"F5","text":"On March 21, 2018, the reporting person was granted 14,375 PRSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each PRSU represents a contingent right to receive one share of the Company's common stock upon vesting, with one-third of the PRSUs vesting upon each achievement of the Performance Milestones through the calendar year 2020. On December 31, 2020, one of the Performance Milestones was achieved, resulting in the vesting of 4,792 PRSUs."},{"field":"shares","element":"transactionShares","label":"F5","text":"On March 21, 2018, the reporting person was granted 14,375 PRSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each PRSU represents a contingent right to receive one share of the Company's common stock upon vesting, with one-third of the PRSUs vesting upon each achievement of the Performance Milestones through the calendar year 2020. On December 31, 2020, one of the Performance Milestones was achieved, resulting in the vesting of 4,792 PRSUs."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On March 21, 2018, the reporting person was granted 14,375 PRSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each PRSU represents a contingent right to receive one share of the Company's common stock upon vesting, with one-third of the PRSUs vesting upon each achievement of the Performance Milestones through the calendar year 2020. On December 31, 2020, one of the Performance Milestones was achieved, resulting in the vesting of 4,792 PRSUs."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On March 21, 2018, the reporting person was granted 14,375 PRSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each PRSU represents a contingent right to receive one share of the Company's common stock upon vesting, with one-third of the PRSUs vesting upon each achievement of the Performance Milestones through the calendar year 2020. On December 31, 2020, one of the Performance Milestones was achieved, resulting in the vesting of 4,792 PRSUs."}],"balance_after":0,"derivative":{"exercise_date":"2020-12-31","underlying":"Common Stock","underlying_shares":4792},"source":{"system":"sec-edgar","filing":"0001209191-21-001712","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919121001712/doc4.xml","form_type":"4"}},{"id":2920659,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Restricted Stock Unit (performance-based)","published_at":"2021-01-05T20:55:19.000Z","date":"2020-12-31","kind":"grant","acquired":true,"shares":4792,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"On March 21, 2018, the reporting person was granted 14,375 PRSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each PRSU represents a contingent right to receive one share of the Company's common stock upon vesting, with one-third of the PRSUs vesting upon each achievement of the Performance Milestones through the calendar year 2020. On December 31, 2020, one of the Performance Milestones was achieved, resulting in the vesting of 4,792 PRSUs."},{"field":"date","element":"transactionDate","label":"F5","text":"On March 21, 2018, the reporting person was granted 14,375 PRSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each PRSU represents a contingent right to receive one share of the Company's common stock upon vesting, with one-third of the PRSUs vesting upon each achievement of the Performance Milestones through the calendar year 2020. On December 31, 2020, one of the Performance Milestones was achieved, resulting in the vesting of 4,792 PRSUs."},{"field":"shares","element":"transactionShares","label":"F5","text":"On March 21, 2018, the reporting person was granted 14,375 PRSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each PRSU represents a contingent right to receive one share of the Company's common stock upon vesting, with one-third of the PRSUs vesting upon each achievement of the Performance Milestones through the calendar year 2020. On December 31, 2020, one of the Performance Milestones was achieved, resulting in the vesting of 4,792 PRSUs."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On March 21, 2018, the reporting person was granted 14,375 PRSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each PRSU represents a contingent right to receive one share of the Company's common stock upon vesting, with one-third of the PRSUs vesting upon each achievement of the Performance Milestones through the calendar year 2020. On December 31, 2020, one of the Performance Milestones was achieved, resulting in the vesting of 4,792 PRSUs."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"On March 21, 2018, the reporting person was granted 14,375 PRSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each PRSU represents a contingent right to receive one share of the Company's common stock upon vesting, with one-third of the PRSUs vesting upon each achievement of the Performance Milestones through the calendar year 2020. On December 31, 2020, one of the Performance Milestones was achieved, resulting in the vesting of 4,792 PRSUs."}],"balance_after":4792,"derivative":{"exercise_date":"2020-12-31","underlying":"Common Stock","underlying_shares":4792},"source":{"system":"sec-edgar","filing":"0001209191-21-001712","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919121001712/doc4.xml","form_type":"4"}},{"id":2920658,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Stock Option (right to buy)","published_at":"2021-01-05T20:55:19.000Z","date":"2020-12-31","kind":"grant","acquired":true,"shares":9583,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F4","text":"On March 21, 2018, the reporting person was granted an option to purchase 28,750 shares of common stock pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. The award had performance-based vesting, with one-third of the award vesting upon each achievement of three scientific and regulatory milestones through the calendar year 2020 (the \"Performance Milestones\"). On December 31, 2020, one of the Performance Milestones was achieved, resulting in the vesting of the option as to 9,583 shares."},{"field":"shares","element":"transactionShares","label":"F4","text":"On March 21, 2018, the reporting person was granted an option to purchase 28,750 shares of common stock pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. The award had performance-based vesting, with one-third of the award vesting upon each achievement of three scientific and regulatory milestones through the calendar year 2020 (the \"Performance Milestones\"). On December 31, 2020, one of the Performance Milestones was achieved, resulting in the vesting of the option as to 9,583 shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On March 21, 2018, the reporting person was granted an option to purchase 28,750 shares of common stock pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. The award had performance-based vesting, with one-third of the award vesting upon each achievement of three scientific and regulatory milestones through the calendar year 2020 (the \"Performance Milestones\"). On December 31, 2020, one of the Performance Milestones was achieved, resulting in the vesting of the option as to 9,583 shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On March 21, 2018, the reporting person was granted an option to purchase 28,750 shares of common stock pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. The award had performance-based vesting, with one-third of the award vesting upon each achievement of three scientific and regulatory milestones through the calendar year 2020 (the \"Performance Milestones\"). On December 31, 2020, one of the Performance Milestones was achieved, resulting in the vesting of the option as to 9,583 shares."}],"balance_after":9583,"derivative":{"exercise_price":23.46,"exercise_date":"2020-12-31","expiration_date":"2028-03-20","underlying":"Common Stock","underlying_shares":9583},"source":{"system":"sec-edgar","filing":"0001209191-21-001712","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919121001712/doc4.xml","form_type":"4"}},{"id":2920657,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2021-01-05T20:55:19.000Z","date":"2021-01-05","kind":"sale","acquired":false,"shares":2078,"price":55.86,"value":116077.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold in sell-to-cover transaction in order to satisfy withholding taxes to be paid upon the vesting of 4,792 performance-based restricted stock units (\"PRSUs\") on December 31, 2020."}],"balance_after":51990,"source":{"system":"sec-edgar","filing":"0001209191-21-001712","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919121001712/doc4.xml","form_type":"4"}},{"id":2920656,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2021-01-05T20:55:19.000Z","date":"2020-12-31","kind":"exercise","acquired":true,"shares":4792,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 568 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on December 31, 2020."}],"balance_after":54068,"source":{"system":"sec-edgar","filing":"0001209191-21-001712","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919121001712/doc4.xml","form_type":"4"}},{"id":2958612,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Stock Option (right to buy)","published_at":"2020-12-03T18:42:08.000Z","date":"2020-12-01","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 110,208 shares as of December 1, 2020."}],"balance_after":105000,"derivative":{"exercise_price":13.88,"expiration_date":"2027-01-05","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001209191-20-061650","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919120061650/doc4.xml","form_type":"4"}},{"id":2958611,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2020-12-03T18:42:08.000Z","date":"2020-12-01","kind":"sale","acquired":false,"shares":257,"price":39.46,"value":10141.22,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.22 to $39.66, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2020 at each separate price."}],"balance_after":48708,"source":{"system":"sec-edgar","filing":"0001209191-20-061650","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919120061650/doc4.xml","form_type":"4"}},{"id":2958610,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2020-12-03T18:42:08.000Z","date":"2020-12-01","kind":"sale","acquired":false,"shares":1522,"price":38.49,"value":58581.78,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.19 to $39.05, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2020 at each separate price."}],"balance_after":48965,"source":{"system":"sec-edgar","filing":"0001209191-20-061650","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919120061650/doc4.xml","form_type":"4"}},{"id":2958609,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2020-12-03T18:42:08.000Z","date":"2020-12-01","kind":"sale","acquired":false,"shares":1585,"price":37.73,"value":59802.05,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.19 to $38.11, inclusive.  Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 1, 2020 at each separate price."}],"balance_after":50487,"source":{"system":"sec-edgar","filing":"0001209191-20-061650","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919120061650/doc4.xml","form_type":"4"}},{"id":2958608,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2020-12-03T18:42:08.000Z","date":"2020-12-01","kind":"exercise","acquired":true,"shares":5000,"price":13.88,"value":69400.0,"ownership":{"direct":true},"balance_after":52072,"source":{"system":"sec-edgar","filing":"0001209191-20-061650","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919120061650/doc4.xml","form_type":"4"}},{"id":2975261,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Stock Option (right to buy)","published_at":"2020-11-18T19:55:13.000Z","date":"2020-11-18","kind":"exercise","acquired":false,"shares":848,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 52,864 shares as of November 16, 2020."}],"balance_after":71090,"derivative":{"exercise_price":18.3,"expiration_date":"2027-12-11","underlying":"Common Stock","underlying_shares":848},"source":{"system":"sec-edgar","filing":"0001209191-20-059272","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919120059272/doc4.xml","form_type":"4"}},{"id":2975260,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Stock Option (right to buy)","published_at":"2020-11-18T19:55:13.000Z","date":"2020-11-16","kind":"exercise","acquired":false,"shares":562,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 52,864 shares as of November 16, 2020."}],"balance_after":71938,"derivative":{"exercise_price":18.3,"expiration_date":"2027-12-11","underlying":"Common Stock","underlying_shares":562},"source":{"system":"sec-edgar","filing":"0001209191-20-059272","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919120059272/doc4.xml","form_type":"4"}},{"id":2975259,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Stock Option (right to buy)","published_at":"2020-11-18T19:55:13.000Z","date":"2020-11-16","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and vested in full on February 3, 2020."}],"balance_after":105117,"derivative":{"exercise_price":6.83,"expiration_date":"2026-02-02","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-20-059272","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919120059272/doc4.xml","form_type":"4"}},{"id":2975258,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2020-11-18T19:55:13.000Z","date":"2020-11-18","kind":"sale","acquired":false,"shares":624,"price":35,"value":21840.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":47072,"source":{"system":"sec-edgar","filing":"0001209191-20-059272","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919120059272/doc4.xml","form_type":"4"}},{"id":2975257,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2020-11-18T19:55:13.000Z","date":"2020-11-18","kind":"exercise","acquired":true,"shares":848,"price":18.3,"value":15518.4,"ownership":{"direct":true},"balance_after":47696,"source":{"system":"sec-edgar","filing":"0001209191-20-059272","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919120059272/doc4.xml","form_type":"4"}},{"id":2975256,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2020-11-18T19:55:13.000Z","date":"2020-11-16","kind":"sale","acquired":false,"shares":414,"price":35,"value":14490.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":46848,"source":{"system":"sec-edgar","filing":"0001209191-20-059272","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919120059272/doc4.xml","form_type":"4"}},{"id":2975255,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2020-11-18T19:55:13.000Z","date":"2020-11-16","kind":"exercise","acquired":true,"shares":562,"price":18.3,"value":10284.6,"ownership":{"direct":true},"balance_after":47262,"source":{"system":"sec-edgar","filing":"0001209191-20-059272","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919120059272/doc4.xml","form_type":"4"}},{"id":2975254,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2020-11-18T19:55:13.000Z","date":"2020-11-16","kind":"sale","acquired":false,"shares":3595,"price":34.51,"value":124063.45,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.09 to $34.86, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2020 at each separate price."}],"balance_after":46700,"source":{"system":"sec-edgar","filing":"0001209191-20-059272","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919120059272/doc4.xml","form_type":"4"}},{"id":2975253,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2020-11-18T19:55:13.000Z","date":"2020-11-16","kind":"sale","acquired":false,"shares":2020,"price":33.75,"value":68175.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.08 to $34.03, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2020 at each separate price."}],"balance_after":50295,"source":{"system":"sec-edgar","filing":"0001209191-20-059272","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919120059272/doc4.xml","form_type":"4"}},{"id":2975252,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2020-11-18T19:55:13.000Z","date":"2020-11-16","kind":"exercise","acquired":true,"shares":10000,"price":6.83,"value":68300.0,"ownership":{"direct":true},"balance_after":52315,"source":{"system":"sec-edgar","filing":"0001209191-20-059272","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919120059272/doc4.xml","form_type":"4"}},{"id":2989775,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Stock Option (right to buy)","published_at":"2020-11-06T16:41:02.000Z","date":"2020-11-04","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 107,812 shares as of November 4, 2020."}],"balance_after":110000,"derivative":{"exercise_price":13.88,"expiration_date":"2027-01-05","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001209191-20-057300","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919120057300/doc4.xml","form_type":"4"}},{"id":2989774,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2020-11-06T16:41:02.000Z","date":"2020-11-04","kind":"sale","acquired":false,"shares":3364,"price":28,"value":94192.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":42315,"source":{"system":"sec-edgar","filing":"0001209191-20-057300","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919120057300/doc4.xml","form_type":"4"}},{"id":2989773,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2020-11-06T16:41:02.000Z","date":"2020-11-04","kind":"exercise","acquired":true,"shares":5000,"price":13.88,"value":69400.0,"ownership":{"direct":true},"balance_after":45679,"source":{"system":"sec-edgar","filing":"0001209191-20-057300","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919120057300/doc4.xml","form_type":"4"}},{"id":3005289,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Stock Option (right to buy)","published_at":"2020-10-16T20:58:05.000Z","date":"2020-10-15","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and vested in full on February 3, 2020."}],"balance_after":115117,"derivative":{"exercise_price":6.83,"expiration_date":"2026-02-02","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-20-055196","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919120055196/doc4.xml","form_type":"4"}},{"id":3005288,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2020-10-16T20:58:05.000Z","date":"2020-10-15","kind":"sale","acquired":false,"shares":156,"price":24.55,"value":3829.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":40679,"source":{"system":"sec-edgar","filing":"0001209191-20-055196","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919120055196/doc4.xml","form_type":"4"}},{"id":3005287,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2020-10-16T20:58:05.000Z","date":"2020-10-15","kind":"sale","acquired":false,"shares":5459,"price":24.19,"value":132053.21,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.53 to $24.49, inclusive.  Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 15, 2020 at each separate price."}],"balance_after":40835,"source":{"system":"sec-edgar","filing":"0001209191-20-055196","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919120055196/doc4.xml","form_type":"4"}},{"id":3005286,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2020-10-16T20:58:05.000Z","date":"2020-10-15","kind":"exercise","acquired":true,"shares":10000,"price":6.83,"value":68300.0,"ownership":{"direct":true},"balance_after":46294,"source":{"system":"sec-edgar","filing":"0001209191-20-055196","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919120055196/doc4.xml","form_type":"4"}},{"id":3028556,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Stock Option (right to buy)","published_at":"2020-09-17T16:55:28.000Z","date":"2020-09-15","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and vested in full on February 3, 2020."}],"balance_after":125117,"derivative":{"exercise_price":6.83,"expiration_date":"2026-02-02","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-20-050945","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919120050945/doc4.xml","form_type":"4"}},{"id":3028555,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2020-09-17T16:55:28.000Z","date":"2020-09-15","kind":"sale","acquired":false,"shares":5615,"price":21.04,"value":118139.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":36294,"source":{"system":"sec-edgar","filing":"0001209191-20-050945","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919120050945/doc4.xml","form_type":"4"}},{"id":3028554,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2020-09-17T16:55:28.000Z","date":"2020-09-15","kind":"exercise","acquired":true,"shares":10000,"price":6.83,"value":68300.0,"ownership":{"direct":true},"balance_after":41909,"source":{"system":"sec-edgar","filing":"0001209191-20-050945","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919120050945/doc4.xml","form_type":"4"}},{"id":3051137,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Stock Option (right to buy)","published_at":"2020-08-20T16:13:50.000Z","date":"2020-08-18","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and vested in full on February 3, 2020."}],"balance_after":135117,"derivative":{"exercise_price":6.83,"expiration_date":"2026-02-02","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-20-047713","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919120047713/doc4.xml","form_type":"4"}},{"id":3051136,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2020-08-20T16:13:50.000Z","date":"2020-08-18","kind":"sale","acquired":false,"shares":5615,"price":21,"value":117915.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":31909,"source":{"system":"sec-edgar","filing":"0001209191-20-047713","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919120047713/doc4.xml","form_type":"4"}},{"id":3051135,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2020-08-20T16:13:50.000Z","date":"2020-08-18","kind":"exercise","acquired":true,"shares":10000,"price":6.83,"value":68300.0,"ownership":{"direct":true},"balance_after":37524,"source":{"system":"sec-edgar","filing":"0001209191-20-047713","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919120047713/doc4.xml","form_type":"4"}},{"id":3080531,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Stock Option (right to buy)","published_at":"2020-07-17T16:18:12.000Z","date":"2020-07-15","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and vested in full on February 3, 2020."}],"balance_after":145117,"derivative":{"exercise_price":6.83,"expiration_date":"2026-02-02","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-20-042820","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919120042820/doc4.xml","form_type":"4"}},{"id":3080530,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2020-07-17T16:18:12.000Z","date":"2020-07-15","kind":"sale","acquired":false,"shares":5615,"price":22.7,"value":127460.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":27524,"source":{"system":"sec-edgar","filing":"0001209191-20-042820","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919120042820/doc4.xml","form_type":"4"}},{"id":3080529,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2020-07-17T16:18:12.000Z","date":"2020-07-15","kind":"exercise","acquired":true,"shares":10000,"price":6.83,"value":68300.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 857 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on June 30, 2020."}],"balance_after":33139,"source":{"system":"sec-edgar","filing":"0001209191-20-042820","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919120042820/doc4.xml","form_type":"4"}},{"id":3105555,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Stock Option (right to buy)","published_at":"2020-06-18T17:00:17.000Z","date":"2020-06-16","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and vested in full on February 3, 2020."}],"balance_after":155117,"derivative":{"exercise_price":6.83,"expiration_date":"2026-02-02","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-20-037647","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919120037647/doc4.xml","form_type":"4"}},{"id":3105554,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2020-06-18T17:00:17.000Z","date":"2020-06-16","kind":"sale","acquired":false,"shares":5615,"price":21,"value":117915.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":22282,"source":{"system":"sec-edgar","filing":"0001209191-20-037647","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919120037647/doc4.xml","form_type":"4"}},{"id":3105553,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2020-06-18T17:00:17.000Z","date":"2020-06-16","kind":"exercise","acquired":true,"shares":10000,"price":6.83,"value":68300.0,"ownership":{"direct":true},"balance_after":27897,"source":{"system":"sec-edgar","filing":"0001209191-20-037647","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919120037647/doc4.xml","form_type":"4"}},{"id":3132282,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Stock Option (right to buy)","published_at":"2020-05-28T17:23:45.000Z","date":"2020-05-26","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and has vested in full on February 3, 2020."}],"balance_after":165117,"derivative":{"exercise_price":6.83,"expiration_date":"2026-02-02","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-20-032648","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919120032648/doc4.xml","form_type":"4"}},{"id":3132281,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2020-05-28T17:23:45.000Z","date":"2020-05-26","kind":"sale","acquired":false,"shares":5615,"price":21.21,"value":119094.15,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"262,210 of these shares are held by Rivak Capital LLC (\"Rivak\"). Mr. Rivera is a member and the general manager of Rivak and has voting and dispositive power over these shares."}],"balance_after":280107,"source":{"system":"sec-edgar","filing":"0001209191-20-032648","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919120032648/doc4.xml","form_type":"4"}},{"id":3132280,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Common Stock","published_at":"2020-05-28T17:23:45.000Z","date":"2020-05-26","kind":"exercise","acquired":true,"shares":10000,"price":6.83,"value":68300.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"262,210 of these shares are held by Rivak Capital LLC (\"Rivak\"). Mr. Rivera is a member and the general manager of Rivak and has voting and dispositive power over these shares."}],"balance_after":285722,"source":{"system":"sec-edgar","filing":"0001209191-20-032648","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919120032648/doc4.xml","form_type":"4"}},{"id":3227643,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-03-04T17:28:15.000Z","date":"2020-03-02","kind":"grant","acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on March 2, 2020 with respect to 125,000 shares of Common Stock, with 25% vesting on January 1, 2021 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter."}],"balance_after":125000,"derivative":{"exercise_price":13.4,"expiration_date":"2030-03-01","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0000899243-20-006976","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000089924320006976/doc4.xml","form_type":"4"}},{"id":3723394,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Stock Option (right to buy)","published_at":"2018-12-20T16:25:34.000Z","date":"2018-12-18","kind":"grant","acquired":true,"shares":71000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on December 18, 2018 with respect to 71,000 shares of Common Stock, with 25% vesting on December 18, 2019 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter."}],"balance_after":71000,"derivative":{"exercise_price":14.58,"expiration_date":"2028-12-17","underlying":"Common Stock","underlying_shares":71000},"source":{"system":"sec-edgar","filing":"0001209191-18-063664","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919118063664/doc4.xml","form_type":"4"}},{"id":4086657,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Stock Option (right to buy)","published_at":"2018-01-29T15:30:33.000Z","date":"2018-01-25","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on January 25, 2018 with respect to 25,000 shares of Common Stock, with 25% vesting on January 25, 2019 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter."}],"balance_after":25000,"derivative":{"exercise_price":22.78,"expiration_date":"2028-01-24","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-18-005803","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919118005803/doc4.xml","form_type":"4"}},{"id":4131853,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel"}}],"security":"Stock Option (right to buy)","published_at":"2017-12-14T16:08:46.000Z","date":"2017-12-12","kind":"grant","acquired":true,"shares":72500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on December 12, 2017 with respect to 72,500 shares of Common Stock, with 25% vesting on December 12, 2018 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter."}],"balance_after":72500,"derivative":{"exercise_price":18.295,"expiration_date":"2027-12-11","underlying":"Common Stock","underlying_shares":72500},"source":{"system":"sec-edgar","filing":"0001209191-17-065664","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919117065664/doc4.xml","form_type":"4"}},{"id":4293055,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel & Ops"}}],"security":"Common Stock","published_at":"2017-06-05T07:57:37.000Z","date":"2017-06-01","kind":"grant","acquired":true,"shares":8400,"price":12.0327,"value":101074.68,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.98 to $12.04, inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 594 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on December 31, 2016."}],"balance_after":8994,"source":{"system":"sec-edgar","filing":"0001209191-17-037514","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919117037514/doc4.xml","form_type":"4"}},{"id":4494107,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":140607,"kind":"person","name":"Rivera Jose E","position":1,"cik":"0001671870","reported_name":"Rivera Jose E","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel & Ops"}}],"security":"Stock Option (right to buy)","published_at":"2017-01-10T20:05:46.000Z","date":"2017-01-06","kind":"grant","acquired":true,"shares":115000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on January 6, 2017 with respect to 115,000 shares of Common Stock, with 25% vesting on January 6, 2018 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter."}],"balance_after":115000,"derivative":{"exercise_price":13.88,"expiration_date":"2027-01-05","underlying":"Common Stock","underlying_shares":115000},"source":{"system":"sec-edgar","filing":"0001209191-17-003284","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671870/000120919117003284/doc4.xml","form_type":"4"}}]}